NFKBIA
Overview
NFKBIA (IkBα) encodes the primary inhibitor of the NF-kB transcription factor family. By sequestering NF-kB dimers in the cytoplasm, NFKBIA acts as a tumor suppressor in B-cell lymphomas; loss-of-function mutations release constitutive NF-kB activity, which drives proliferation and survival.
Alterations observed in the corpus
- NFKBIA somatic mutations were identified in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing of 55 tumors (Broad cohort), implicating NF-kB pathway dysregulation as a recurrent oncogenic mechanism PMID:22343534
- NFKBIA copy-number gain (amplification) identified in recurrent GISTIC peaks in metastatic cSCC (n=29). PMID:25589618
- Alterations in NFKBIA were associated with poorer prognosis specifically in GCB DLBCL (1001-patient cohort) PMID:28985567
Cancer types (linked)
- DLBCL: somatic loss-of-function mutations; NF-kB pathway activation PMID:22343534
Co-occurrence and mutual exclusivity
- Co-occurs with MYD88 mutations in the NF-kB pathway activation context in DLBCL PMID:22343534
Therapeutic relevance
- NF-kB pathway (including NFKBIA loss and MYD88 gain-of-function) was highlighted as a targetable pathway in DLBCL PMID:22343534
Open questions
- The relative contributions of NFKBIA loss versus MYD88 gain-of-function to NF-kB activation in individual DLBCL tumors remain to be fully characterized PMID:22343534
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25589618
This page was processed by crosslinker on 2026-05-14. - PMID:28985567
This page was processed by wiki-cli on 2026-05-15.